A Phase 1 Study to Evaluate TGI-6 in Subjects With Locally Advanced/Metastatic Solid Tumors

Advanced or Metastatic Solid Tumors Clinical Trial

Official title:

A Phase 1 Study to Investigate the Safety, Tolerability, Pharmacokinetics/ Pharmacodynamics, and Antitumor Activity of TGI-6 as Monotherapy in Subjects With Locally Advanced/Metastatic Solid Tumors

Clinical Trial Details — Status: Recruiting

Administrative data

• NCT number: NCT06374173
• Other study ID #: TGI6-T1-01
• Status: Recruiting
• Phase: Phase 1
• Start date: January 3, 2024
• Est. completion date: December 2027

Study information

• Verified date: April 2024
• Source: Hefei TG ImmunoPharma Co., Ltd.
• Contact: Xiaohu Zheng, Doctorate
• Phone: +86 0551-62861151
• Email: xiaohu.zheng[@]tgimmunopharma.com
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

A Phase 1 Study to Evaluate TGI-6 in Subjects with Locally Advanced/Metastatic Solid Tumors

Description:

This is a Phase 1, multicenter, open-label, two-parts, FIH study to evaluate the tolerability, safety, PK/PD, and preliminary anti-tumor activity of TGI-6 as monotherapy in subjects with unresectable locally advanced/metastatic CRC, or subjects with confirmed B7-H6-positive locally advanced/metastatic solid tumors. The study consists of two parts: a dose escalation part (Phase 1a) and a dose expansion part (Phase 1b). For each subject in the two parts, the study will include a screening period (up to 28 days), a treatment period (until treatment discontinuation), and a follow-up period including safety and survival follow-up.

Recruitment information / eligibility

• Status: Recruiting
• Enrollment: 123
• Est. completion date: December 2027
• Est. primary completion date: September 2027
• Accepts healthy volunteers: No
• Gender: All
• Age group: 18 Years and older

Eligibility

Inclusion Criteria:

1. Male or female subjects age =18 years at the time of informed consent.

2. Phase 1a: Subjects with histologically or cytologically diagnosed unresectable locally advanced/metastatic CRC. Or subjects with confirmed B7-H6-positive unresectable locally advanced/metastatic solid tumors, mainly but not limited to TNBC, HCC, HNSCC, SCLC, OC, GC, pancreatic cancer, and melanoma. Phase 1b Cohort 1: Subjects must have pathologically documented, definitively diagnosed unresectable locally advanced and/or metastatic CRC. Phase 1b Cohort 2: Subjects must have pathologically documented, definitively diagnosed unresectable locally advanced and/or metastatic solid tumors with B7-H6-positive, mainly but not limited to TNBC, HCC, HNSCC, SCLC, OC, GC, pancreatic cancer, and melanoma.

3. Phase 1a or Phase1b Cohort 2: Subjects should have progressed despite all standard therapy or be intolerant of all standard therapy, or for whom no standard therapy exists. (Standard therapies are defined as treatments recommended by local guidelines, including, but not limited to, chemotherapy, radiation, target therapies based on mutation status, immunotherapy, and surgery in general).

4. All subjects except subjects with CRC must agree to the collection of tumor samples for confirmation of B7-H6 expression status in a central lab.

5. Subjects in Phase 1a must have at least one evaluable lesion as defined by Response Evaluation Criteria in Solid Tumors (RECIST) v1.1. Subjects in Phase 1b must have least one measurable lesion as defined per RECIST v1.1 which has not received radiotherapy (or progressive disease after radiotherapy).

6. ECOG PS (Appendix 5) of 0~2.

7. Life expectancy =3 months.

8. Subjects have sufficient baseline organ function and laboratory data .

9. Woman of childbearing potential must have a negative serum pregnancy test within 7 days prior to treatment.

10. Female subjects of childbearing potential or male subjects with a partner of childbearing potential must agree to use effective contraception at the time of informed consent and continuing through the study until 6 months after the last dose of TGI-6.

Exclusion Criteria:

1. Subject with known active central nervous system (CNS) primary tumor or metastases.

2. History of intercurrent severe chronic or active infections.

3. Has a history of active autoimmune diseases .

4. Has a history of symptomatic interstitial lung disease.

5. Toxicities of prior therapies have not been resolved to Grade =1 or baseline as per NCI-CTCAE v5.0, except for alopecia, skin hyperpigmentation, Grade 2 neuropathy and Grade 2 endocrinopathy that is well controlled by replacement therapy.

6. Subjects with severe or uncontrolled cardiovascular disorder requiring treatment.

7. Prior allogenic or autologous bone marrow transplantation or other solid organ transplantation.

8. Has a known additional malignancy that is progressing or has required active treatment within the past 3 years .

9. Evidence of clinically significant immunosuppression .

10. Presence of uncontrolled pleural effusion, pericardial effusion or ascites requiring recurrent drainage procedures .

11. Previously treated with the following anti-tumor therapy (prior to the first dose of TGI-6): 1) Previous treated with any B7-H6-targeting therapy. 2) Chemotherapy, target therapy, immunotherapy, or other anticancer therapy within 28 days or 5 half-lives, whichever is

shorter, prior to the first dose of study treatment, except:

1. Washout period for nitrosoureas or mitomycin is =6 weeks.

2. =5 half-lives or 2 weeks (whichever is longer) for fluoropyrimidines or small-molecule targeted agents.

3. Washout period for herbal therapy with anticancer indications is =2 weeks. 3) Prior radiotherapy =4 weeks prior to the first dose of study treatment, with the exception of a single fraction of radiotherapy for the purposes of palliation, which is permitted. 4) Subject participated in any other clinical study and has received an investigational product within 28 days prior to the first dose of TGI-6.

12. Has received systematic immunomodulatory drugs within 14 days before the first dose of study drug, such as thymosin, IL-2, and interferon (IFN).

13. Has received a live vaccine within 4 weeks prior to the first dose of study drug.

14. Has a recent major surgery within 4 weeks prior to the first dose of study drug or is expected to undergo major surgery during the study.

15. Subject requiring anticoagulant treatment which cannot be safely interrupted, if medically needed for a study procedure (e.g., biopsy) based on the opinion of the Investigator.

16. Has a known psychiatric or substance abuse disorder that would interfere with the subject's ability to cooperate with the requirements of the study.

17. Pregnancy or lactation. 18. Has known hypersensitivity to either the drug substances or inactive ingredients in the drug product.

19. Pre-existing other serious medical conditions, familial or endemic disease that, in the opinion of the investigator, will interfere with planned staging, treatment, and follow-up, subject compliance, or will place the subject at high risk for treatment-related complications.

20. Subjects who are unwilling or unable to comply with study procedures and study restrictions, or in the judgment of the investigator, would make the subject inappropriate for entry into this study.

Related Conditions & MeSH terms

• Advanced or Metastatic Solid Tumors
• Neoplasms

Intervention

Drug:
• TGI-6 Injection
TGI-6 will be administered intravenously at a dose and schedule as specified for the respective study part and cohort.

Locations

Country	Name	City	State
China	Beijing Cancer Hospital	Beijing

Sponsors (1)

Lead Sponsor	Collaborator
Hefei TG ImmunoPharma Co., Ltd.

Country where clinical trial is conducted

China, 

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	Dose-limiting Toxicity (DLT)	The incidence of DLTs during the DLT assessment period.	First 21 days of treatment.
Primary	Dose-Finding	Determination of the MTD or maximum tested dose, and the RP2D.	Approximately 3 years.
Primary	Frequency and Severity of Adverse Events (AE)	The incidences and percentages of patients experiencing AEs summarized by NCI CTCAE version 5.0 grade and by causality.	Screening to 30 days from last dose
Secondary	Pharmacokinetics of TGI-6	Maximum Plasma Concentration (Cmax)	Day 1 of dosing through 7 days post last dose
Secondary	Pharmacokinetics of TGI-6	Area Under the Curve (AUC)	Day 1 of dosing through 7 days post last dose
Secondary	Number of subjects with Anti-TGI-6 antibody positive	Immunogenicity of TGI-6 monotherapy	Day 1 of dosing through 7 days post last dose
Secondary	Objective Response Rate (ORR)	ORR according to RECIST v1.1	Approximately 3 years.
Secondary	Duration of Response (DoR)	Time from the date measurement criteria are first met for PR or CR to the date measurement criteria are first met for progressive disease.	Approximately 3 years
Secondary	Disease Control Rate (DCR)	The proportion of subjects who have best overall response of CR or PR, or stable disease (SD).	Approximately 3 years.
Secondary	Progression Free Survival (PFS)	Time from the date of initiation of study therapy to the date measurement criteria are first met for progressive disease or death from any cause, whichever occurs first.	Approximately 3 years.
Secondary	Overall Survival (OS)	Time from the date of initiation of study therapy to the date of death from any cause.	Approximately 3 years.